MarketPeel
Insider Trading Intelligence
Pricing
…
GO

Gilmore Neil O'neill

EDIT
CEO · EDITAS MEDICINE, INC. · CIK 0001742084
FILING MIX · LIFETIME57%/43%
BUYS
16
SELLS
12
TOTAL VALUE
$1.05M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
276,859
AVG SELL PX
$6.40
TRADE KIND
SHOWING 28 / 28
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by Gilmore Neil O'neill, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+30.00%+4.85%+0.45%+4.41%+4.93%—
14d10+50.00%-2.95%+0.72%-3.66%-6.07%—
30d10+70.00%-1.48%+1.02%-2.50%-14.82%—
60d10+70.00%-2.99%+2.76%-5.75%-11.68%—
90d10+70.00%-6.14%+4.22%-18.78%-13.22%—
180d10(1 pending)+55.56%-7.59%+9.17%-23.50%-15.00%—
1y10(3 pending)+57.14%-16.31%+18.03%-46.22%-55.77%—
2y10(7 pending)+100.00%-70.31%+39.91%-119.90%-119.90%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
EDIT · 248,313 shares · as of Jun 3, 2026
0253,800507,600761,4001,015,2002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 12 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
15,380$2.70$41.5K248,313Jun 3, 2026Jun 5, 2026 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
1,015,200——1,015,200Mar 12, 2026Mar 16, 2026 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
5,394$2.02$10.9K263,693Mar 3, 2026Mar 4, 2026 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
5,603$2.15$12.1K269,087Dec 3, 2025Dec 4, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
5,592$2.60$14.5K274,690Sep 3, 2025Sep 4, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
15,192$1.72$26.2K280,282Jun 3, 2025Jun 4, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
828,000——828,000Mar 8, 2025Mar 27, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
175,000——175,000Mar 8, 2025Mar 27, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
16,632$1.71$28.5K295,474Mar 4, 2025Mar 5, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
1,618$2.08$3.4K312,106Dec 3, 2024Dec 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
1,555$3.42$5.3K313,724Sep 4, 2024Sep 6, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
12,191$5.50$67.0K315,279Jun 4, 2024Jun 6, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
77,824$9.42$732.9K327,470Mar 5, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
72,212——405,294Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
392,100——392,100Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
130,700——260,869Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
72,213——333,082Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
6,486$9.50$61.6K130,169Jun 5, 2023Jun 7, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
50,000——136,655Mar 2, 2023Mar 6, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Mar 2, 2023Mar 6, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
950,209——950,209Jun 2, 2022Jun 6, 2022 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
86,655——86,655Jun 2, 2022Jun 6, 2022 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,000——60,000Mar 3, 2021Mar 5, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——29,070Mar 3, 2021Mar 5, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——28,546Mar 3, 2021Mar 10, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, R&D & CMO
524$86.97$45.6K13,546Feb 28, 2021Mar 10, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,700——14,070Feb 28, 2020Feb 28, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,500——37,500Feb 28, 2020Feb 28, 2020 ↗View →
Other insiders · EDIT
Loading peer insiders…
About this filer
CIK 0001742084
ROLE
CEO
PRIMARY
EDIT
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001742084DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback